{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:20:02Z","timestamp":1790774402164,"version":"4.1.0"},"reference-count":49,"publisher":"Japan Atherosclerosis Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2019,10,1]]},"DOI":"10.5551\/jat.48330","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T22:37:24Z","timestamp":1549492644000},"page":"890-914","source":"Crossref","is-referenced-by-count":26,"title":["Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan"],"prefix":"10.5551","volume":"26","author":[{"given":"Hung","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Insured Medical Care Management, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Powen","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Lo-Hsu Medical Foundation Lotung Poh-Ai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hui","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Lo-Hsu Medical Foundation Lotung Poh-Ai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Ito","sequence":"additional","affiliation":[{"name":"Research and Development Center, Denka-Seiken Company, Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Kawasaki Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst J","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Cardiovascular Nutrition Laboratory, Human Nutrition Research Center on Aging at Tufts University, and Tufts University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masumi","family":"Ai","sequence":"additional","affiliation":[{"name":"Department of Insured Medical Care Management, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Siegel RD, Cupples A, Schaefer EJ, and Wilson PW: Apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study, Metabolism. 1996; 45: 1267-1272","DOI":"10.1016\/S0026-0495(96)90246-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ai M, Tanaka A, Ogita K, Sekinc M, Numano F, Numano F, and Reaven GM: Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes, J Am Coll Cardiol. 2001; 38: 1628-1632","DOI":"10.1016\/S0735-1097(01)01611-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, and Wilson PW: Elevated remnantlike particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care, 2002; 25: 989-994","DOI":"10.2337\/diacare.25.6.989"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hirano T, Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb. 2018; 25: 771-782","DOI":"10.5551\/jat.RV17023"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Brannick B, and Dagogo-Jack S, Prediabetes and cardiovascular disease: pathophysiology and interventions for prevention and risk reduction. Endocrinol Metab Clin North Am. 2018; 47: 33-50","DOI":"10.1016\/j.ecl.2017.10.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, and Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998; 316: 823-828","DOI":"10.1136\/bmj.316.7134.823"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Py\u00f6r\u00e4l\u00e4 K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, and Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997; 20: 614-620","DOI":"10.2337\/diacare.20.4.614"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Goldberg RB, Mellies MJ, Sacks FM, Moy\u00e9 LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, and Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998; 98: 2513-2519","DOI":"10.1161\/01.CIR.98.23.2513"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, and Tonkin A: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003; 26: 2713-2721","DOI":"10.2337\/diacare.26.10.2713"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Collins R, Armitage J, Parish S, Sleigh P, and Peto R: MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361: 2005-2016","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, and CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364: 685-696","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D\u2019agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O\u2019Donnel CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Sorlie P, Stone NJ, and Wilson PWF: 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2935-2959","DOI":"10.1016\/j.jacc.2013.11.005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, and Wilson PWF: 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2889-2934","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes \u20142018. Diabetes Care. 2018; 41: S86-S104","DOI":"10.2337\/dc18-S009"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, and Sabatine MS: Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016; 316: 1289-1297","DOI":"10.1001\/jama.2016.13985"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM, Minissian MB, Orringer CE, SC Smith and Writing Committee: 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016; 68: 92-125","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"17","unstructured":"17) DAROC Clinical Practice Guidelines for Diabetes Care2018, <i>Taiwan, Diabetes Association of the ROC<\/i>, 2018"},{"key":"18","unstructured":"18) Taiwan National Health Insurance Medication Prescription Guidelines- 2018, Section 2 \u2013 Cardiovascular-renal drugs, <i>Taiwan, Ministry of Health and Welfare, National Health Insurance Administration <\/i>"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, and Yokote K: Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan\u20142012 version. J Atheroscler Thromb. 2013; 20: 517-523","DOI":"10.5551\/jat.15792"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-1574","DOI":"10.1056\/NEJMoa1001282"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, and Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988; 260: 1917-1921","DOI":"10.1001\/jama.260.13.1917"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PWF and Schaefer EJ: Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992; 12: 187-195","DOI":"10.1161\/01.ATV.12.2.187"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) McNamara JR, Jenner JL, Li Z, Wilson PW, and Schaefer EJ: Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb. 1992; 12: 1284-1290","DOI":"10.1161\/01.ATV.12.11.1284"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Hirano T, Ito Y, Saegusa H, Yoshino G: A novel and simple method for quantification of small, dense LDL. J Lipid Res. 2003; 44: 2193-2201","DOI":"10.1194\/jlr.D300007-JLR200"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ito Y, Fujimura M, Ohta M, Hirano T: Development of a homogeneous assay for measurement of small dense LDL cholesterol. CLIN CHEM. 2011; 57: 57-65","DOI":"10.1373\/clinchem.2010.149559"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Koba S, Yokota Y, Hirano T, Ito Y, Ban Y, Tsunoda F, Sato T, Shoji M, Suzuki H, Geshi E, Kobayashi Y and Katagiri T: Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb. 2008; 15: 250-260","DOI":"10.5551\/jat.E572"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, Wilson PW, and Schaefer EJ: Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010; 56: 967-976","DOI":"10.1373\/clinchem.2009.137489"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Arai H, Kokubo Y, Watanabe M, Sawamura T, Ito Y, Minagawa A, Okamura T, and Miyamato Y: Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study. J Atheroscler Thromb. 2013; 20: 195-203","DOI":"10.5551\/jat.14936"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, Couper D, Virani SS, Kathiresan S, Boerwinkle E, and Ballantyne CM: Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014; 34: 1069-1077","DOI":"10.1161\/ATVBAHA.114.303284"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Tsai MY, Steffen BT, Guan W, McClelland RL, Warnick R, McConnell J, Hoefner DM, and Remaley AT: New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: the Multi-ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2014; 34: 196-201","DOI":"10.1161\/ATVBAHA.113.302401"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) M\u00e4rz W, Scharnagl H, Winkler K, Tiran A, Nauck M, Boehm BO, and Winkelmann BR: Low-density lipoprotein triglycerides associated with low-grade systemic inflam mation, adhesion molecules, and angiographic coronary artery disease, the Ludwigshafen Risk and Cardiovascular Health study. Circulation. 2004; 110: 3068-3074","DOI":"10.1161\/01.CIR.0000146898.06923.80"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ito Y, Ohta M, Ikezaki H, Hirao Y, Machida A, Schaefer EJ, and Furusyo N: Development and population results of a fully automated homogeneous assay for LDL triglyceride. JALM. 2017; 2: 746-756","DOI":"10.1373\/jalm.2017.024554"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Saeed A, Feofanova EV, Yu B, Sun W, Virani SS, Nambi V, Coresh J, Guild CS, Boerwinkle E, Ballantyne CM, and Hoogeveen RC: Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018; 72: 156-169","DOI":"10.1016\/j.jacc.2018.04.050"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hsu P, Ai M, Kanda E, Yu NC, Chen HL, Chen HW, Cheng MH, Kohzuma T, Schaefer EJ, and Yoshida M: A comparison of glycated albumin and glycosylated hemoglobin for the screening of diabetes mellitus in Taiwan. Atherosclerosis, 2015; 242: 327-333","DOI":"10.1016\/j.atherosclerosis.2015.07.037"},{"key":"35","unstructured":"35) Obesity definition: Health Promotion Administration. Ministry of Health and Welfare, Taiwan ROC. (http:\/\/health99.hpa.gov.tw\/OnlinkHealth\/BMI.html) last access 3rd January 2019"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Chang HC, Yang HC, Chang HY, Yeh CJ, Chen HH, Huang KC, and Pan WH. Morbid obesity in Taiwan: Prevalence, trends, associated social demographics, and lifestyle factors. PLoS ONE 2017; 12: e0169577","DOI":"10.1371\/journal.pone.0169577"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Japan Society for the Study of Obesity. New Criteria for \u2018Obesity Disease\u2019 in Japan. The Examination Committee of Criteria for \u2018Obesity Disease\u2019 in Japan. Circ J. 2002; 66: 987-992","DOI":"10.1253\/circj.66.987"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Otokozawa S, Ai M, Asztalos BF, White CC, Demissie-Banjaw S, Cupples LA, Nakajima K, Wilson PWF, and Schaefer, E. J. Direct assessment of plasma low density lipoprotein and high density lipoprotein cholesterol levels and coronary heart disease: results from the Framingham Offspring Study. Atherosclerosis. 2010; 213: 251-255","DOI":"10.1016\/j.atherosclerosis.2010.02.041"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Hirao Y, Nakajima K, Machida T, Murakami M, Ito Y: Development of a novel homogeneous assay for remnant lipoprotein particle holesterol. JALM. 2018; 3: 26-36","DOI":"10.1373\/jalm.2017.024919"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Qi Y, Liu J, Wang W, Wang M, Zhao F, Sun J, Liu J and Zhao D: Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk: A community-based cohort study. J Clin Lipidol. 2018; 12: 89-98","DOI":"10.1016\/j.jacl.2017.11.003"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Ito Y, Satoh N, Ishii T, Kumakura J, and Hirano T: Development of a homogeneous assay for measurement of high-density lipoprotein-subclass cholesterol. Clin Chim Acta. 2014; 427: 86-93","DOI":"10.1016\/j.cca.2013.09.009"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Takahashi Y, Ito Y, Sakurai T, Wada N, Nagasaka A, Fujikawa M, Chiba H, and Hui SP: A Two-step homoge neous assay for apoE-containing HDL-cholesterol. Ann Clin Biochem. 2018: 56; 123-132","DOI":"10.1177\/0004563218795212"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Turner RC, Holman RR, Matthews D, Hockaday TDR, and Peto J: Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism. 1979; 28: 1086-1096","DOI":"10.1016\/0026-0495(79)90146-X"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, and Turner RC: Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419","DOI":"10.1007\/BF00280883"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, and Schaefer EJ: Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2008; 101: 315-318","DOI":"10.1016\/j.amjcard.2007.08.035"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Ikezaki H, Ai M, Schaefer EJ, Otokozawa S, Asztalos BF, Nakajima K, Zhou Y, Liu CT, Jacques PF, Cupples LA, and Furusyo N: Ethnic differences in glucose homeostasis markers between the Kyushu-Okinawa Population Study and the Framingham Offspring Study. Sci Rep. 2016; 6: 36725","DOI":"10.1038\/srep36725"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Ikezaki H, Ai M, Schaefer EJ, Otokozawa S, Asztalos BF, Nakajima K, Zhou Y, Liu CT, Jacques PF, Cupples LA, and Furusyo N: Cardiovascular disease prevalence and insulin resistance in the Kyushu\u2013Okinawa Population Study and the Framingham Offspring Study. J Clin Lipidol. 2017; 11: 348-356","DOI":"10.1016\/j.jacl.2017.01.014"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Furusyo N, Ai M, Okazaki M, Ikezaki H, Ihara T, Hayashi T, Hiramine S, Ura K, Kohzuma T, Schaefer EJ and Hayashi J: Serum cholesterol and triglyceride reference ranges of twenty lipoprotein subclasses for healthy Japanese men and women. Atherosclerosis, 2013; 231: 238- 245","DOI":"10.1016\/j.atherosclerosis.2013.09.008"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/10\/26_48330\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T13:56:29Z","timestamp":1662904589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/10\/26_48330\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.48330","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}